Copyright
©The Author(s) 2022.
World J Hepatol. Aug 27, 2022; 14(8): 1608-1620
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1608
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1608
Table 2 Survival per radiologic response category
| Radiological response | Total n | Overall survival, mo (mean ± SEM) | n of deaths (%) | n alive at study closure (%) |
| Progressive disease | 16 | 8.8 ± 2.0 | 15 (93.7) | 1 (6.3) |
| Stable disease | 6 | 10.4 ± 2.1 | 5 (83.3) | 1 (16.7) |
| Partial response | 3 | Not assessable | 2 (66.7) | 1 (33.3) |
| Complete response | 4 | Not assessable | 0 (0) | 4 (100) |
| Overall | 29 | 14.5 ± 2.1 | 22 (75.9) | 7 (24.1) |
- Citation: De Wilde N, Vonghia L, Francque S, De Somer T, Bagdadi A, Staub E, Lambrechts J, Bucalau AM, Verset G, Van Steenkiste C. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma. World J Hepatol 2022; 14(8): 1608-1620
- URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1608.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1608